Mesoblast Share Price Up, Nears Major Milestone (ASX:MSB)

By ,

The share price of Mesoblast Ltd [ASX:MSB] is up on the back of news the company is due to complete their first interim analysis in early September.

This is for their Phase 3 trial of their lead product for COVID-19 Acute Respiratory Distress Syndrome (ARDS).

MSB shares are up 4.68%, to trade at $4.03 at the time of writing.

MSB Share Price Chart - Mesoblast

Source: Optuma

What’s happening at Mesoblast?

The company’s primary goal is to develop ‘innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.

But they quickly turned their attention to acute respiratory distress syndrome (ARDS) related to COVID-19.

Right now, there are no approved treatments for ARDS in patients with COVID-19, which is the primary cause of death for suffers of COVID-19.

In a recent announcement Mesoblast Chief Executive Dr Silviu Itescu stated:

Remestemcel-L has two imminent major milestones, the interim analysis in the ongoing Phase 3 trial of remestemcel-L in COVID-19 patients with acute respiratory distress syndrome and the FDA advisory committee panel review of our submission for potential approval of RYONCIL™.

The ongoing trials of remestemcel-L showed that patients at Mt Sinai Hospital in New York with moderate to severe ARDS were successfully taken off a ventilator and discharged from hospital within a median of 10 days.

This was shown to be true in nine out of 12 cases of 75% of the patients.

So promising early signs for the treatment are there.

MSB share price chart looks bullish

With the ongoing trails of Remestemcel-L and no end in sight for the COVID-19 pandemic, MSB may be well-placed for a bright future.

MSB Share Price Chart 2 - Mesoblast


Looking at the MSB share price, back in January 2020 the 50-day moving average (green line) crossed over the 200-day moving average (red line).

Since then it has moved further up and away, indicating a bullish outlook.

With the MSB share price sitting at $4.03 at the time of writing, on reasonable volume should the movement up continue the next level that may provide resistance is $4.50 — being the most recent high, this may prove to be a very strong level.

Should the price turn and fall, then the levels of $3.42 and $3.07 may become the focus on the downside.


Carl Wittkopp,
For Money Morning

PS: Four well-positioned small-cap stocks: These innovative Aussie companies are well-placed to capitalise on post-lockdown megatrends. Click here to learn more.


About Carl Wittkopp

Carl Wittkopp writes for Money Morning and has a diploma in Financial Planning. He specialises in technical analysis.

Mesoblast [ASX:MSB] Shares Fall 12% On Litigation Update

Biotech stock Mesoblast [ASX:MSB] plunged 12% on Tuesday after updating the market on a second class action lawsuit lodged against it.

Mesoblast [ASX:MSB] Shares Fall On Q3 Results

Biotech company Mesoblast [ASX:MSB] released its third quarter results today with MSB shares trading down following the update.

MSB Share Price Up — Trial Drug Helps Against Heart Attacks (ASX:MSB)

Up-and-coming biotech player Mesoblast [ASX:MSB] is on the up today. The regenerative medicine company announced some promising results from a Phase III drug trial from data that was shared at the American Heart Association’s annual ‘Scientific Sessions’, an exhibition of the latest findings and insights into all things heart health related.

Mesoblast Shares Tumble as Losses Widen (ASX:MSB)

The MSB share price down 14%. The Mesoblast [ASX:MSB] posted a FY21 net loss of $98.8 million as the FDA asks for further trials of MSB’s emergency COVID treatment…  

Mesoblast Share Price Bounce Back on Positive Trial Data (ASX:MSB)

It seems 2021 continues to be a tough year for the ever-volatile Mesoblast Ltd [ASX:MSB]. Thankfully though, today has brought some relief to shareholders. The MSB share price is up 7.38%…

Mesoblast Share Price Down — Secures a Dire Cash Injection (ASX:MSB)

Seven months ago Mesoblast Ltd [ASX:MSB] was on a tear. This high-flying biotech looked like it had the makings of something great.
Today though, that couldn’t be further from the truth. The MSB share price is down 5.08%.